Baseline characteristics of patients with IgD myeloma
| Characteristic . | Grouping . | Old trials(MM IV, V VI, and VIII), nN = 44 . | Recent trials(MM IX and MM XI), N = 70 . | P . |
|---|---|---|---|---|
| n (%) . | n (%) . | |||
| Age | ≤65 y | 35 (80) | 38 (54) | .0088 |
| >65 y | 9 (20) | 32 (46) | ||
| Sex | Male | 31 (70) | 48 (69) | .99 |
| Female | 13 (30) | 22 (31) | ||
| Serum creatinine (µmol/L) | <130 | 22 (50) | 48 (68) | .04 |
| 130-200 | 6 (14) | 11 (16) | ||
| >200 | 16 (36) | 11 (16) | ||
| Missing | 0 (0) | 0 (0) | ||
| Serum β 2 microglobulin | <3.5 | 3 (7) | 16 (23) | .0044 |
| (mg/L) | 3.5-5.5 | 7 (16) | 15 (21) | |
| >5.5 | 33 (75) | 30 (43) | ||
| Missing | 1 (2) | 9 (13) | ||
| ISS stage | Stage I | 2 (4.5) | 15 (21) | .0045 |
| Stage II | 7 (16) | 15 (21) | ||
| Stage III | 33 (75) | 30 (43) | ||
| Missing | 2 (4.5) | 10 (14) | ||
| Performance status | 0-2 | 15 (34) | 64 (91) | <.0001 |
| 3-4 | 27 (61) | 4 (6) | ||
| Missing | 2 (5) | 2 (3) | ||
| Lytic lesions | Present | 34 (77) | 37 (53) | .03 |
| Absent | 7 (16) | 21 (30) | ||
| Not known/missing | 3 (7) | 12 (17) | ||
| Serum calcium (mmol/L) | ≤2.6 | 20 (45) | 54 (77) | <.0001 |
| >2.6 | 10 (23) | 16 (23) | ||
| Missing | 14 (32) | 0 (0) | ||
| Hemoglobin (g/L) | <100 | 20 (45) | 39 (56) | .07 |
| ≥100 | 21 (48) | 31 (44) | ||
| Missing | 3 (7) | 0 (0) | ||
| Platelet count (×109/L) | <150 | 10 (23) | 7 (10) | .0016 |
| ≥150 | 29 (66) | 63 (90) | ||
| Missing | 5 (11) | 0 (0) | ||
| IgD serum paraprotein quantification (g/L) | <10 | 24 (55) | 36 (51) | .9338 |
| =>10 | 14 (32) | 23 (33) | ||
| Missing | 6 (13) | 11 (16) | ||
| Light chain type | Λ | 29 (66) | 43 (61) | .3944 |
| κ | 14 (32) | 21 (30) | ||
| Missing | 1 (2) | 6 (9) | ||
| Bone marrow plasma cell (%) | <20 | 6 (14) | 11 (16) | .26 |
| 20-50 | 9 (20) | 25 (36) | ||
| >50 | 15 (34) | 20 (28) | ||
| Missing | 14 (32) | 14 (20) |
| Characteristic . | Grouping . | Old trials(MM IV, V VI, and VIII), nN = 44 . | Recent trials(MM IX and MM XI), N = 70 . | P . |
|---|---|---|---|---|
| n (%) . | n (%) . | |||
| Age | ≤65 y | 35 (80) | 38 (54) | .0088 |
| >65 y | 9 (20) | 32 (46) | ||
| Sex | Male | 31 (70) | 48 (69) | .99 |
| Female | 13 (30) | 22 (31) | ||
| Serum creatinine (µmol/L) | <130 | 22 (50) | 48 (68) | .04 |
| 130-200 | 6 (14) | 11 (16) | ||
| >200 | 16 (36) | 11 (16) | ||
| Missing | 0 (0) | 0 (0) | ||
| Serum β 2 microglobulin | <3.5 | 3 (7) | 16 (23) | .0044 |
| (mg/L) | 3.5-5.5 | 7 (16) | 15 (21) | |
| >5.5 | 33 (75) | 30 (43) | ||
| Missing | 1 (2) | 9 (13) | ||
| ISS stage | Stage I | 2 (4.5) | 15 (21) | .0045 |
| Stage II | 7 (16) | 15 (21) | ||
| Stage III | 33 (75) | 30 (43) | ||
| Missing | 2 (4.5) | 10 (14) | ||
| Performance status | 0-2 | 15 (34) | 64 (91) | <.0001 |
| 3-4 | 27 (61) | 4 (6) | ||
| Missing | 2 (5) | 2 (3) | ||
| Lytic lesions | Present | 34 (77) | 37 (53) | .03 |
| Absent | 7 (16) | 21 (30) | ||
| Not known/missing | 3 (7) | 12 (17) | ||
| Serum calcium (mmol/L) | ≤2.6 | 20 (45) | 54 (77) | <.0001 |
| >2.6 | 10 (23) | 16 (23) | ||
| Missing | 14 (32) | 0 (0) | ||
| Hemoglobin (g/L) | <100 | 20 (45) | 39 (56) | .07 |
| ≥100 | 21 (48) | 31 (44) | ||
| Missing | 3 (7) | 0 (0) | ||
| Platelet count (×109/L) | <150 | 10 (23) | 7 (10) | .0016 |
| ≥150 | 29 (66) | 63 (90) | ||
| Missing | 5 (11) | 0 (0) | ||
| IgD serum paraprotein quantification (g/L) | <10 | 24 (55) | 36 (51) | .9338 |
| =>10 | 14 (32) | 23 (33) | ||
| Missing | 6 (13) | 11 (16) | ||
| Light chain type | Λ | 29 (66) | 43 (61) | .3944 |
| κ | 14 (32) | 21 (30) | ||
| Missing | 1 (2) | 6 (9) | ||
| Bone marrow plasma cell (%) | <20 | 6 (14) | 11 (16) | .26 |
| 20-50 | 9 (20) | 25 (36) | ||
| >50 | 15 (34) | 20 (28) | ||
| Missing | 14 (32) | 14 (20) |